Literature DB >> 20976811

Minimum standards for urodynamic practice in the UK.

Gurpreet Singh1, Malcolm Lucas, Lucia Dolan, Stephanie Knight, Carmel Ramage, Philip Toozs Hobson.   

Abstract

AIM: This paper reports on the recent publication and wide distribution of a joint statement on minimum standards for urodynamic practice in the UK.
METHODS: A multidisciplinary working party were tasked with creating standards for both training and certification in urodynamics, as well as explicit standards for a framework of service delivery. This was done through a process of extensive consultation with relevant professional bodies.
RESULTS: The standards suggest a modular structure to urodynamics training, and make recommendations on minimum workload for individuals and departments, the need for multidisciplinary team working and for regular audit.
CONCLUSIONS: This is the first attempt to standardise urodynamics practice nationally. The document is available on the United Kingdom Continence Society websitewww.ukcs.uk.net.
© 2010 Wiley-Liss, Inc.

Mesh:

Year:  2010        PMID: 20976811     DOI: 10.1002/nau.20883

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  10 in total

1.  Self-assessment of treatment compliance with antimuscarinic drugs and lower urinary tract condition among women with urinary incontinence.

Authors:  Kirill Kosilov; Sergey Loparev; Irina Kuzina; Olga Shakirova; Natalya Zhuravskaya; Alexandra Lobodenko
Journal:  Int Urogynecol J       Date:  2017-04-20       Impact factor: 2.894

2.  Radiation exposure during videourodynamics in women.

Authors:  Ilias Giarenis; Jonathan Phillips; Heleni Mastoroudes; Sushma Srikrishna; Dudley Robinson; Cornelius Lewis; Linda Cardozo
Journal:  Int Urogynecol J       Date:  2013-02-22       Impact factor: 2.894

3.  Randomized controlled trial of cyclic and continuous therapy with trospium and solifenacin combination for severe overactive bladder in elderly patients with regard to patient compliance.

Authors:  Kirill V Kosilov; Sergay A Loparev; Marina A Ivanovskaya; Liliya V Kosilova
Journal:  Ther Adv Urol       Date:  2014-12

4.  Caffeine as a Probable Factor for Increased Risk of OAB Development in Elderly People.

Authors:  Kirill V Kosilov; Sergay A Loparev; Marina A Ivanovskaya; Liliya V Kosilova
Journal:  Curr Urol       Date:  2016-09-20

5.  Effectiveness of combined high-dosed trospium and solifenacin depending on severity of OAB symptoms in elderly men and women under cyclic therapy.

Authors:  Kirill Kosilov; Sergey Loparev; Marina Iwanowskaya; Liliya Kosilova
Journal:  Cent European J Urol       Date:  2014-04-17

6.  A new tool for self-evaluation of adherence to antimuscarinic drugs treatment in patients with urinary incontinence.

Authors:  Kirill V Kosilov; Sergay A Loparev; Irina G Kuzina; Olga V Shakirova; Yuliya I Gainullina; Liliya V Kosilova; Alexandra S Prokofyeva
Journal:  Arab J Urol       Date:  2017-11-16

7.  Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride.

Authors:  Kirill V Kosilov; Irina G Kuzina; Vladimir Kuznetsov; Ekaterina K Kosilova
Journal:  Prostate Int       Date:  2020-02-25

8.  Efficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients.

Authors:  Kirill Kosilov; Irina Kuzina; Vladimir Kuznetsov; Olga Barabash; Ekaterina Fedorishcheva
Journal:  Asian J Urol       Date:  2021-04-20

9.  The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection.

Authors:  Kirill V Kosilov; Sergay A Loparev; Marina A Ivanovskaya; Liliya V Kosilova
Journal:  Arab J Urol       Date:  2015-08-05

10.  Maintenance of the therapeutic effect of two high-dosage antimuscarinics in the management of overactive bladder in elderly women.

Authors:  Kirill Kosilov; Sergey Loparev; Marina Ivanovskaya; Liliya Kosilova
Journal:  Int Neurourol J       Date:  2013-12-31       Impact factor: 2.835

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.